Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Neck Cancer
Provided By Globe Newswire
Last update: Jul 26, 2022
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn” or the “Company”) today announces results from the INSPIRE phase 2 trial of IRX-2, a multi-cytokine biologic immunotherapy, in patients with newly diagnosed stage II, III, or IVA squamous cell carcinoma of the oral cavity.
BlackRock Technology and Private Equity Term Trust
NYSE:BTX (2/21/2025, 8:04:35 PM)
After market: 7.64 -0.02 (-0.26%)7.66
-0.2 (-2.54%)
Find more stocks in the Stock Screener
